|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | State of the art biological therapies in pancreatic cancer显示文摘Pancreatic ductal adenocarcinoma(PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib(a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials(closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment. | mariacristina di marco elisa grassi sandra durante silvia vecchiarelli andrea palloni marina macchini riccardo casadei claudio ricci riccardo panzacchi donatella santini guido biasco | 2016 | World Journal of Gastrointestinal Oncology2016，8，1： | 3 |
| 2 | Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases显示文摘Background:Hepatocellular carcinoma(HCC)is one of the most frequent causes of cancer-related death.Sorafenib,a multitarget angiogenesis inhibitor,is an approved frontline treatment for advanced HCC in Western countries,although a complete response(CR)to treatment is infrequently reported.Capecitabine,an oral fluoropyrimidine,has been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib.To date,how-ever,only one case of sustained CR to metronomic capecitabine has been reported.Case presentation:We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was obtained.In the first case,capecitabine was administered as first line therapy;in the second case,capecitabine was used after intolerance to sorafenib;while in the third case,capecitabine was administered after sorafenib failure.Conclusion:Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases. | Giovanni Brandi Michela Venturi Stefania De Lorenzo Francesca Garuti Giorgio Frega Andrea Palloni Ingrid Garajovà Francesca Abbati Gioconda Saccoccio Rita Golfieri Maria Abbondanza Pantaleo Maria Aurelia Barbera | 2018 | Cancer Communications2018，38，1： | 2 |
| 3 | Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?显示文摘Dear Editor:In the last two decades,the indications of liver transplantation(LT)for primary and secondary hepatobiliary malignancies have been increasingly expanded.Although this attractive option still represents the“last court of appeal”in cancer patients,the role of LT is well established in hepatocellular carcinoma(HCC),where transplantation has also demonstrated a benefit for selected patients affected by peri-hilar cholangiocarcinoma,intrahepatic cholangiocarcinoma,and neuroendocrine tumors[1].Recently,the interest in LT in liver-limited stage IV colorectal cancer(CRC)has increased due to recent advances in transplantation techniques that have led to a re-evaluation of this approach. | Giovanni Brandi Angela Dalia Ricci Alessandro Rizzo Chiara Zanfi Simona Tavolari Andrea Palloni Stefania De Lorenzo Matteo Ravaioli Matteo Cescon | 2020 | Cancer Communications2020，40，9： | 1 |
| 4 | Obesity and excess mortality among the elderly in the United States and Mexico显示文摘 | Malena Monteverde Kenya Noronha Alberto Palloni | 2010 | Demography2010，47，1： | 1 |
| 5 | Population and Deforestation in Costa Rica显示文摘 | Luis Rosero-Bixby Alberto Palloni | 1998 | Population and Environment1998，，2： | 1 |
| 6 | Obesityand excess mortality amongthe elderly in the United States and Mexico 显示文摘 | Malena Monteverde Kenya Noronha Alberto Palloni etal | 2010 | Demography2010，47，1： | 1 |
| 7 | Survey data for the study of aging in Latin America and the Caribbean显示文摘 | Wong R Pelatez M Palloni A | 2006 | Journal of Aging and Health2006，18，2： | 1 |
| 8 | Paradox lost: explaining the Hispanic adult mortality advantage 显示文摘 | Palloni A Arias E | 2004 | Demography2004，41，： | 1 |
| 9 | Paradox lost : explaining the Hispanicadult mortality advantage 显示文摘 | Palloni A Arias E | 2004 | Demography2004，41，38： | 1 |
| 10 | Obesityand excess mortality among the elderly in the United States andMexico显示文摘 | MalenaMonteveide Kenya Noronha Alberto Palloni | 2010 | Demography2010，47，1： | 1 |
| 11 | Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation:A case report显示文摘BACKGROUND Pancreatic acinar cell carcinoma (PACC) is a rare type of malignant pancreatic cancer that represents approximately 1%of all pancreatic neoplasms.Due to its very low incidence,only a few retrospective studies are available.Although surgery is the first choice for treatment,most patients experience recurrence(mainly in the liver) and there are no clear recommendations for patients with advanced disease.CASE SUMMARY We report two patients with PACC treated with sturgery who experienced tumour recurrence in the liver.Patient 1 carried a germline mutation in the APC gene.Both patients were treated with gemcitabine plus oxaliplatin and gemcitabine plus capecitabine as first-and second-line therapies,respectively.After a favoturable response to chemotherapy,the patients underwent radiofrequency ablation of the remaining liver metastases.For patient 1,we documented a relapse in the liver after a disease-free period of 9 mo,and treatment with gemcitabine plus capecitabine was restarted.The patient achieved a complete response,and he remains alive without evidence of disease recurrence after six years.After radiofrequency ablation,patient 2 experienced disease-free survival for 21 mo,when peritoneal relapse was diagnosed and treated with chemotherapy.The patient achieved a stable disease state for nearly two years;nevertheless,further progressive disease was documented,and he died seven years after the first relapse.CONCLUSION PACC presents different biological behaviours than pancreatic adenocarcinoma.Multidisciplinary treatment involving local ablative therapies may be considered for PACC. | Mariacristina Di Marco Riccardo Carloni Stefania De Lorenzo Elisa Grassi Andrea Palloni Francesca Formica Stefano Brocchi Daria Maria Filippini Rita Golfieri Giovanni Brandi | 2020 | World Journal of Clinical Cases2020，8，7： | 0 |
| 12 | Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report显示文摘BACKGROUND Pancreatic mucinous cystadenocarcinoma(MCAC)is a rare malignancy with a poor prognosis when it presents metastases at diagnosis.Due to its very low incidence,there are no clear recommendations for the treatment of advanced disease.Olaparib(an oral PARP inhibitor)has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline BRCA1/2 mutations.Herein,we report the first case of a germline BRCA1 mutated unresectable MCAC which was effectively treated with olaparib.CASE SUMMARY A 41-year-old woman,without personal or family history of cancer,was diagnosed with ovarian and peritoneal metastases of MCAC.She underwent 12 cycles of gemcitabine plus oxaliplatin(GEMOX)obtaining a partial response and allowing radical surgery.One year later,local recurrence was documented,and other 12 cycles of GEMOX were administered obtaining a complete response.Seven years later,another local recurrence,not amenable to surgical resection,was diagnosed.She started FOLFIRINOX(oxaliplatin,irinotecan,leucovorin and fluorouracil),obtaining a partial response after 8 cycles.Given the excellent response to platinum-based chemotherapy,BRCA testing was performed,and a BRCA1 germline mutation was detected.She was switched to maintenance olaparib due to chemotherapy-related toxicities and achieved an almost complete metabolic response,with a reduction in the diameter of the lesion,after three months of therapy.CONCLUSION The current case suggests the beneficial effect of olaparib in BRCA mutated MCAC.However,further studies are required. | Mariacristina Di Marco Riccardo Carloni Stefania De Lorenzo Cristina Mosconi Andrea Palloni Elisa Grassi Daria Maria Filippini Angela Dalia Ricci Alessandro Rizzo Alessandro Di Federico Donatella Santini Daniela Turchetti Claudio Ricci Carlo Ingaldi Laura Alberici Francesco Minni Rita Golfieri Giovanni Brandi Riccardo Casadei | 2020 | World Journal of Gastrointestinal Oncology2020，12，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员